Literature DB >> 21562823

CYP isoform specificity toward drug metabolism: analysis using common feature hypothesis.

M Ramesh1, Prasad V Bharatam.   

Abstract

Three dimensional pharmacophoric maps were generated for each isoforms of CYP2C9, CYP2D6 and CYP3A4 separately using independent training sets consist of highly potent substrates (seven substrates for each isoform). HipHop module of CATALYST software was used in the generation of pharmacophore models. The best pharmacophore model was chosen out of the several models on the basis of (i) highest ranking score, (ii) better fit value among training set, (iii) capability to screen substrates from data set and (iv) efficiency to identify the isoform specificity. The individual pharmacophore models (CYP2C9-hypo1, CYP2D6-hypo1 and CYP3A4-hypo1) are characterized by the pharmacophoric features XZDH, RPZH and XYZHH for the CYP2C9, CYP2D6 and CYP3A4 respectively. Each of the chosen models was validated by using data sets of CYP substrates. This comparative study of CYP substrates demonstrates the importance of acidic character along with HBD and HBAl features for CYP2C9, basic character with ring aromatic features for CYP2D6 and hydrophobic features for CYP3A4. Acidity, basicity and hydrophobicity features arising from the functional groups of the substrates are also responsible for demonstrating CYP isoform specificity. Hence, these chemical features are incorporated in the decision tree along with pharmacophore maps. Finally, a decision tree based on chemical features and pharmacophore features was generated to identify the isoform specificity of novel query molecule toward the three isoforms.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21562823     DOI: 10.1007/s00894-011-1105-5

Source DB:  PubMed          Journal:  J Mol Model        ISSN: 0948-5023            Impact factor:   1.810


  53 in total

1.  Influence of N-substitution of 7-methoxy-4-(aminomethyl)-coumarin on cytochrome P450 metabolism and selectivity.

Authors:  J Venhorst; R C Onderwater; J H Meerman; J N Commandeur; N P Vermeulen
Journal:  Drug Metab Dispos       Date:  2000-12       Impact factor: 3.922

2.  Structure-based methods for the prediction of the dominant P450 enzyme in human drug biotransformation: consideration of CYP3A4, CYP2C9, CYP2D6.

Authors:  N Manga; J C Duffy; P H Rowe; M T D Cronin
Journal:  SAR QSAR Environ Res       Date:  2005 Feb-Apr       Impact factor: 3.000

3.  Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite.

Authors:  M Bajpai; L K Roskos; D D Shen; R H Levy
Journal:  Drug Metab Dispos       Date:  1996-12       Impact factor: 3.922

4.  Arginines 97 and 108 in CYP2C9 are important determinants of the catalytic function.

Authors:  M Ridderström; C Masimirembwa; S Trump-Kallmeyer; M Ahlefelt; C Otter; T B Andersson
Journal:  Biochem Biophys Res Commun       Date:  2000-04-21       Impact factor: 3.575

5.  Identification of CYP3A4 as the principal enzyme catalyzing mifepristone (RU 486) oxidation in human liver microsomes.

Authors:  G R Jang; S A Wrighton; L Z Benet
Journal:  Biochem Pharmacol       Date:  1996-09-13       Impact factor: 5.858

6.  Putative active site template model for cytochrome P4502C9 (tolbutamide hydroxylase).

Authors:  B C Jones; G Hawksworth; V A Horne; A Newlands; J Morsman; M S Tute; D A Smith
Journal:  Drug Metab Dispos       Date:  1996-02       Impact factor: 3.922

7.  Metabolism of the tricyclic antidepressant amitriptyline by cDNA-expressed human cytochrome P450 enzymes.

Authors:  O V Olesen; K Linnet
Journal:  Pharmacology       Date:  1997-11       Impact factor: 2.547

8.  Synergistic use of compound properties and docking scores in neural network modeling of CYP2D6 binding: predicting affinity and conformational sampling.

Authors:  Peter S Bazeley; Sridevi Prithivi; Craig A Struble; Richard J Povinelli; Daniel S Sem
Journal:  J Chem Inf Model       Date:  2006 Nov-Dec       Impact factor: 4.956

9.  Catalytic roles of CYP2C9 and its variants (CYP2C9*2 and CYP2C9*3) in lornoxicam 5'-hydroxylation.

Authors:  Izumi Iida; Atsunori Miyata; Masayuki Arai; Mitsuyo Hirota; Masayuki Akimoto; Shohei Higuchi; Kaoru Kobayashi; Kan Chiba
Journal:  Drug Metab Dispos       Date:  2004-01       Impact factor: 3.922

10.  The molecular mechanisms of two common polymorphisms of drug oxidation--evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation.

Authors:  U A Meyer; J Gut; T Kronbach; C Skoda; U T Meier; T Catin; P Dayer
Journal:  Xenobiotica       Date:  1986-05       Impact factor: 1.908

View more
  1 in total

1.  The FDA-Approved Drug Cobicistat Synergizes with Remdesivir To Inhibit SARS-CoV-2 Replication In Vitro and Decreases Viral Titers and Disease Progression in Syrian Hamsters.

Authors:  Andrea Savarino; Marina Lusic; Iart Luca Shytaj; Mohamed Fares; Lara Gallucci; Bojana Lucic; Mahmoud M Tolba; Liv Zimmermann; Julia M Adler; Na Xing; Judith Bushe; Achim D Gruber; Ina Ambiel; Ahmed Taha Ayoub; Mirko Cortese; Christopher J Neufeldt; Bettina Stolp; Mohamed Hossam Sobhy; Moustafa Fathy; Min Zhao; Vibor Laketa; Ricardo Sobhie Diaz; Richard E Sutton; Petr Chlanda; Steeve Boulant; Ralf Bartenschlager; Megan L Stanifer; Oliver T Fackler; Jakob Trimpert
Journal:  mBio       Date:  2022-03-01       Impact factor: 7.786

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.